phospho-c-Jun (Ser243)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3173R
英文名称phospho-c-Jun (Ser243)
中文名称磷酸化原癌基因肠-闯耻苍抗体
别 名c-Jun (phospho Ser243); c-Jun (phospho S243); c-Jun (phospho S243); p-c-Jun (phospho S243) ; Transcription factor AP-1; Jun oncogene; JUN; AP 1; AP1; AP-1; Enhancer Binding Protein AP1; Jun Activation Domain Binding Protein; JUN protein; JUNC; p39; Proto oncogene cJun; Transcription Factor AP1; V jun avian sarcoma virus 17 oncogene homolog; vJun Avian Sarcoma Virus 17 Oncogene Homolog; JUN_HUMAN; Activator 1; Proto-oncogene c-Jun; V-jun avian sarcoma virus 17 oncogene homolog.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 转录调节因子
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-c-Jun (Ser243)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep,
产物应用WB=1:500-1000 ELISA=1:2000-5000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=0.2μg /Test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量43kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human c-Jun around the phosphorylation site of Ser73:PL(p-S)PI
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-c-Jun (Ser243)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
C-jun (Oncoprotein C-jun) is a component of the transcription factor AP-1 that binds and activates transcription at TRE/AP-1 elements and appears to be a major downstream target of the SAPK/JNK signaling pathway. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73. Extracellular signals including growth factors, transforming oncoproteins and UV irradiation stimulate phosphorylation of c-Jun at Ser63/73 and activate c-Jun dependent transcription. Mutation of Ser63/73 renders c-Jun nonresponsive to mitogenic and stress induced signaling pathways. The MAP kinase homologue, SAPK/JNK, binds to the N-terminal region of c-Jun and phosphorylates c-Jun at Ser63/73. In addition, the activity of SAPK/JNK is stimulated by the same signals that activate c-Jun.
Function:
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.
Subunit:
Heterodimer with either FOS or BATF3 or ATF7. The ATF7/JUN heterodimer is essential for ATF7 transactivation activity. Interacts with DSIPI; the interaction inhibits the binding of active AP1 to its target DNA (By similarity). Interacts with HIVEP3 and MYBBP1A (By similarity). Interacts with SP1, SPIB and TCF20. Interacts with COPS5; the interaction leads indirectly to its phosphorylation. Component of the SMAD3/SMAD4/JUN/FOS/complex which forms at the AP1 promoter site. The SMAD3/SMAD4 heterodimer acts syngernistically with the JUN/FOS heterodimer to activate transcription in response to TGF-beta. Interacts (via its basic DNA binding and leucine zipper domains) with SMAD3 (via an N-terminal domain); the interaction is required for TGF-beta-mediated transactivation of the SMAD3/SMAD4/JUN/FOS/complex. Interacts with RNF187. Binds to HIPK3.
Subcellular Location:
Nucleus.
Post-translational modifications:
Phosphorylated by CaMK4 and PRKDC; phosphorylation enhances the transcriptional activity. Phosphorylated by HIPK3. Phosphorylated at Thr-239, Ser-243 and Ser-249 by GSK3B; phosphorylation reduces its ability to bind DNA. Phosphorylated by PAK2 at Thr-2, Thr-8, Thr-89, Thr-93 and Thr-286 thereby promoting JUN-mediated cell proliferation and transformation. Phosphorylated by PLK3 following hypoxia or UV irradiation, leading to increase DNA-binding activity.
Acetylated at Lys-271 by EP300.
Similarity:
Belongs to the bZIP family. Jun subfamily.
Contains 1 bZIP (basic-leucine zipper) domain.
SWISS:
P05412
Gene ID:
3725
phospho-c-Jun (Ser243)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-c-Jun (Ser243)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 TRAPPC2 SEDL蛋白抗体
合格 TRAPPC4 SBDN蛋白抗体
合格 合格 TRAPPC5 TRS31蛋白抗体
合格 合格 TRAPPC6B TRAPPC6B蛋白抗体
合格 phospho-STAT3 (Tyr705) 磷酸化信号转导和转录激活因子3抗体
合格 TRAPPCL2 HSPC176蛋白抗体
合格 ILKAP 整合素连接激酶相关丝氨酸/苏氨酸磷酸酶抗体
合格 DILP3 胰岛素样肽3抗体
合格 Cytokeratin 5 + 6 细胞角蛋白5+6抗体
合格 TNFR2 肿瘤坏死因子受体2抗体
合格 Cytokeratin 6 细胞角蛋白6抗体
合格 IMPACT IMPACT蛋白抗体
合格 phospho-Integrin beta 1(Tyr783) 磷酸化整合素β1/Integrin β1抗体
合格 phospho-Integrin beta 1(Tyr795) 磷酸化整合素β1/Integrin β1抗体
合格 VEGF 血管内皮生长因子抗体
合格 INO80 DNA解旋酶INO80抗体
合格 INO80E INO80E蛋白抗体
合格 phospho-Transferrin Receptor (Ser24) 磷酸化转铁蛋白受体抗体
合格 CCL21 **细胞趋化因子CCL21/Exodus 2抗体
合格 INSL5 A chain 胰岛素样肽5 a链抗体
合格 INSL6 胰岛素样肽6抗体
合格 INSM2 胰岛素瘤相关蛋白2抗体
合格 合格 INT11/CPSF3L INT11蛋白抗体
合格 Phospho-Insulin Receptor (Tyr999) 磷酸化胰岛素受体抗体
合格 phospho-GRK2 (Ser670) 磷酸化G蛋白偶合受体激酶2抗体
合格 IQCF5 IQCF5蛋白抗体
合格 XBP1 细胞核转录因子X盒结合蛋白抗体
合格 合格 IQUB IQUB蛋白抗体
合格 IRAK1BP1 白细胞介素1受体相关激酶1结合蛋白1抗体
合格 IRF2BP2 干扰素调节因子2结合蛋白2抗体
合格 IRF5 干扰素调节因子5抗体
合格 TREX2 TREX2蛋白抗体
合格 phospho-TRF1 (Ser219) 磷酸化端粒体复制结合因子1抗体
合格 TRF4-2 拓扑异构酶相关功能蛋白4-2抗体
合格 TRH Receptor 促甲状腺**释放**受体抗体